Treatment News : Treating HIV Very Early May Limit Inflammation, Gut Damage

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Treatment News » April 2014

Most Popular Lessons

The HIV Life Cycle

Shingles

Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

15 Years Ago In POZ


More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to news@poz.com.


emailprint

April 17, 2014

Treating HIV Very Early May Limit Inflammation, Gut Damage

CROI 2014Staring antiretroviral (ARV) therapy immediately after HIV infection may both limit the virus’s toll on the gut lining and also lower the body’s overall chronic inflammatory state, HIVandHepatitis reports. Studying 34 people with acute HIV infection, researchers presented their findings at the Conference on Retroviruses and Opportunistic Infections (CROI) in Boston.

Out of 53,000 screened samples, 13 participants were identified in what’s known as Fibig stage I (FI), which refers to the first acceleration of viral replication following infection. The Fibig stages ultimately lead to FIV, which occurs when the viral load reaches its peak. An additional 21 of the participants were diagnosed at FIII. The study also included various matched controls: five HIV-negative participants and nine treatment-naive people who had been living with the virus for six to 12 months.

The participants underwent gut tissue biopsies upon their entry into the study and again six and 24 months after beginning ARVs.

Those who started therapy during FI maintained a proportion of Th17 cells, which are a T cells that are key to maintaining the gut lining, similar to that of HIV-negative people at the six- and 24-month reads. While progressing through the Fibig stages apparently led to a drop in Th17 cell proportion, the introduction of ARVs prevented additional cell loss. Nevertheless, HIV therapy did not reverse this loss in those who started treatment during FIII.

Those in FI at the study’s outset displayed signs of an increased inflammatory state in both the gut and in peripheral blood, while those in FIII showed much greater signs of inflammation. Starting HIV treatment at FI reduced the inflammatory state to that of HIV-negative people. If treatment didn’t begin until FIII, there was still evidence of an elevated inflammatory state after six and 24 months.

HIV-related chronic inflammation is believed to lead to an increased risk for cardiovascular disease and cognitive impairment.

To read the HIVandHepatitis story, click here.

Search: HIV, gut, inflammation, HIVandHepatitis, early treatment, Conference on Retroviruses and Opportunistic Infections, CROI, Fibig stages, Th17 cells.


Scroll down to comment on this story.



Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules



Show comments (1 total)

 
[Go to top]


Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Poll
Should the U.S. gay blood ban end?
Yes
No

Survey
Smoke Signals

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.